On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.

Welcome to AudioScholar. Today we're summarizing "On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.", from NephJC. Cardiovascular disease is the leading cause of death in patients with advanced chronic kidney disease, yet traditional cardioprotective therapies often fail. Aggressive cholesterol lowering does not reduce cardiovascular death on dialysis, and invasive revascularization has not shown survival benefits in this population. Because of these failures, researchers shifted focus toward targeting hypercoagulability. While large trials like COMPASS demonstrated that adding low-dose rivaroxaban to aspirin reduces major cardiovascular events, these studies systematically excluded patients with stage four or five chronic kidney disease and those on dialysis. Clinicians were left in a difficult position, needing to balance the high ischemic risk of advanced kidney disease against the equally high risk of uremia-induced bleeding, without any direct clinical trial data to guide them.

To address this evidence gap, investigators conducted the TRACK trial, a randomized, quadruple-blind, placebo-controlled study across twelve countries, which did not include the United States. The trial enrolled one thousand four hundred and sixty-three adults with stage four or five chronic kidney disease, including those on dialysis, who had at least one additional cardiovascular risk factor such as diabetes or older age. Participants were randomized to receive either rivaroxaban two point five milligrams twice daily or a matching placebo. The trial was stopped early by the data and safety monitoring board after a median follow-up of one point seven years due to futility and concerns over net harm. The primary composite outcome, which included cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or nonfatal peripheral artery disease events, occurred in twenty-three percent of the rivaroxaban group compared to twenty-one percent of the placebo group. This yielded a hazard ratio of one point zero nine, demonstrating no cardiovascular benefit with rivaroxaban. Furthermore, all-cause mortality was similar between the two groups, with sudden cardiac death being the most common cause of death overall.

While efficacy was absent, safety concerns were prominent. Major bleeding events were significantly higher in the rivaroxaban group, occurring in eight point eight percent of patients compared to six percent in the placebo group. This represents a fifty-one percent relative increase in major bleeding, with the gastrointestinal tract being the most common site of hemorrhage. Notably, this bleeding risk was particularly pronounced among participants aged sixty-five and older, where major bleeding reached ten percent in the rivaroxaban group compared to five point six percent in the placebo group.

These findings provide a clear clinical boundary. For patients with advanced chronic kidney disease who do not have a standard indication for anticoagulation, routine use of low-dose rivaroxaban to prevent cardiovascular events is not supported and carries a substantial risk of harm. The study mirrors historical primary prevention trials with aspirin, confirming that in advanced kidney disease, the bleeding risks of antithrombotic therapy outweigh any potential ischemic protection. Because this summary is based on a single clinical trial report, listeners should consult the primary published literature and official clinical guidelines before making changes to their prescribing practices. That was a summary of On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD., from NephJC. For the full piece, visit the original source. Until next time.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.